Literature DB >> 11578302

Survey of the use of thromboprophylaxis in laparoscopic surgery in Denmark.

T Filtenborg Tvedskov1, M S Rasmussen, P Wille-Jørgensen.   

Abstract

BACKGROUND: The aim of this study was to determine the current use of thromboprophylaxis for laparoscopic surgery in Denmark.
METHODS: Postal questionnaires were sent to all Danish surgical departments that performed laparoscopic surgery according to the National Laparoscopic Cholecystectomy Database.
RESULTS: There was a written protocol for thromboprophylaxis in 93 per cent of the responding departments. In 37 per cent thromboprophylaxis was used for all patients undergoing laparoscopic surgery; only 7 per cent used thromboprophylaxis sporadically. All departments used low molecular weight heparin, 74 per cent in combination with graduated compression stockings. The criteria for using thromboprophylaxis varied greatly; in many departments conversion of the procedure to an open operation was not considered a criterion. Some 20 per cent of the departments reported previous thromboembolic complications following laparoscopic surgery.
CONCLUSION: Despite the widespread use of thromboprophylaxis, symptomatic thromboembolic complications were reported from several departments. Further studies are needed to determine whether laparoscopic surgery should be considered a high-risk procedure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11578302     DOI: 10.1046/j.0007-1323.2001.01856.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  2 in total

1.  Current use of thromboembolism prophylaxis for laparoscopic cholecystectomy patients in Sweden.

Authors:  F Lindberg; M Bjorck; I Rasmussen; D Bergqvist
Journal:  Surg Endosc       Date:  2004-12-02       Impact factor: 4.584

2.  Thromboprophylaxis for lung cancer patients--multimodality assessment of clinician practices, perceptions and decision support tools.

Authors:  M Alexander; S Kirsa; M MacManus; D Ball; B Solomon; K Burbury
Journal:  Support Care Cancer       Date:  2014-02-27       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.